Mohammad Ibtehaz Alam

Dr. Mohammad Ibtehaz Alam

Regenerative Medicine and Skeletal Development, University of Connecticut Health, Farmington, Connecticut, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Mohammad Ibtehaz AlamMohammad Ibtehaz Alam
Mohammad Ibtehaz Alam
MMMegumi Mae
Megumi Mae
FFFatima Farhana
Fatima Farhana
MOMasayuki Oohira
Masayuki Oohira
YYyasunori yamashita
yasunori yamashita
AYAtsutoshi Yoshimura
Atsutoshi Yoshimura
In inflammatory bone diseases such as periodontitis, the nucleotide-binding oligomerization domain, leucine-rich repeat, and pyrin domain-containing 3 (NLRP3) inflammasome accelerates bone resorption by promoting proinflammatory cytokine IL-1β production. However, the role of the NLRP3 inflammasome in physiological bone remodeling remains unclear. Here, we investigated its role in osteoclastogenesis in the presence and absence of lipopolysaccharide (LPS), a Gram-negative bacterial component. When bone marrow macrophages (BMMs) were treated with receptor activator of nuclear factor-κB ligand (RANKL) in the presence of NLRP3 inflammasome inhibitors, osteoclast formation was promoted in the absence of LPS but attenuated in its presence. BMMs treated with RANKL and LPS produced IL-1β, and IL-1 receptor antagonist inhibited osteoclastogenesis, indicating IL-1β involvement. BMMs treated with RANKL alone produced no IL-1β but increased reactive oxygen species (ROS) production. A ROS inhibitor suppressed apoptosis-associated speck-like protein containing a caspase-1 recruitment domain (ASC) speck formation and NLRP3 inflammasome inhibitors abrogated cytotoxicity in BMMs treated with RANKL, indicating that RANKL induces pyroptotic cell death in BMMs by activating the NLRP3 inflammasome via ROS. This suggests that the NLRP3 inflammasome promotes osteoclastogenesis via IL-1β production under infectious conditions, but suppresses osteoclastogenesis by inducing pyroptosis in osteoclast precursors under physiological conditions.

5 September 2021 in Journal of Periodontology
Verified
Journal Article
Closed access
PDF file
SZS.M. Ziauddin
S.M. Ziauddin
Mohammad Ibtehaz AlamMohammad Ibtehaz Alam
Mohammad Ibtehaz Alam
MMMegumi Mae
Megumi Mae
MOMasayuki Oohira
Masayuki Oohira
KHKanako Higuchi
Kanako Higuchi
AYAtsutoshi Yoshimura
Atsutoshi Yoshimura

Verified
Journal Article
Open access
PDF file
MMMegumi Mae
Megumi Mae
Mohammad Ibtehaz AlamMohammad Ibtehaz Alam
Mohammad Ibtehaz Alam
YYyasunori yamashita
yasunori yamashita
YOYukio Ozaki
Yukio Ozaki
KHKanako Higuchi
Kanako Higuchi
AYAtsutoshi Yoshimura
Atsutoshi Yoshimura
Dental calculus (DC) is a common deposit in periodontitis patients. We have previously shown that DC contains both microbial components and calcium phosphate crystals that induce an osteoclastogenic cytokine IL-1β via the NLRP3 inflammasome in macrophages. In this study, we examined the effects of cytokines produced by mouse macrophages stimulated with DC on osteoclastogenesis. The culture supernatants from wild-type (WT) mouse macrophages stimulated with DC accelerated osteoclastogenesis in RANKL-primed mouse bone marrow macrophages (BMMs), but inhibited osteoclastogenesis in RANKL-primed RAW-D cells. WT, but not NLRP3-deficient, mouse macrophages stimulated with DC produced IL-1β and IL-18 in a dose-dependent manner, indicating the NLRP3 inflammasome-dependent production of IL-1β and IL-18. Both WT and NLRP3-deficient mouse macrophages stimulated with DC produced IL-10, indicating the NLRP3 inflammasome-independent production of IL-10. Recombinant IL-1β accelerated osteoclastogenesis in both RANKL-primed BMMs and RAW-D cells, whereas recombinant IL-18 and IL-10 inhibited osteoclastogenesis. These results indicate that DC induces osteoclastogenic IL-1β in an NLRP3 inflammasome-dependent manner and anti-osteogenic IL-18 and IL-10 dependently and independently of the NLRP3 inflammasome, respectively. DC may promote alveolar bone resorption via IL-1β induction in periodontitis patients, but suppress resorption via IL-18 and IL-10 induction in some circumstances.

Verified
Journal Article
Open access
PDF file
Mohammad Ibtehaz AlamMohammad Ibtehaz Alam
Mohammad Ibtehaz Alam
FFFatima Farhana
Fatima Farhana
ESEiko Sakai
Eiko Sakai
Growing evidence suggests that persistent oral infectious diseases (OIDs) contribute to systemic disease, highlighting the importance of understanding their pathogenic mechanisms. Conventional dental treatments, primarily mechanical debridement, surgical intervention, or antimicrobial therapy, often struggle to fully control inflammation or prevent progressive tissue destruction. The nucleotide-binding oligomerization domain, leucine-rich repeat, and pyrin domain-containing 3 (NLRP3) inflammasome is a key regulator of innate immunity, mediating the maturation of proinflammatory cytokines (IL-1β and IL-18) and the pyroptosis-inducing protein gasdermin D. Dysregulated or excessive activation of NLRP3 contributes to the initiation and progression of major oral diseases, including periodontitis, peri-implantitis, pulpitis, and oral mucosal inflammation. Despite growing interest in NLRP3, comprehensive and up-to-date reviews integrating its pathogenic mechanisms and therapeutic potential remain limited. This review summarizes current and past evidence on the role of the NLRP3 inflammasome in oral disease development, highlights emerging pharmacological strategies, and outlines future research directions. Existing studies demonstrate that microbial components and danger signals from injured tissues activate NLRP3, thereby amplifying inflammation, tissue degradation, and bone resorption. Preclinical studies indicate that inflammasome inhibitors and several natural compounds reduce tissue damage; however, their clinical translation remains limited. These findings emphasize the need for deeper understanding of NLRP3-mediated pathways, with translational and clinical research offering promising therapeutic opportunities for oral diseases.

1 February 2021 in Archives of Oral Biology
Verified
Journal Article
Closed access
YOYukio Ozaki
Yukio Ozaki
TKTakaaki Kishimoto
Takaaki Kishimoto
YYyasunori yamashita
yasunori yamashita
TKTakashi Kaneko
Takashi Kaneko
KHKanako Higuchi
Kanako Higuchi
AYAtsutoshi Yoshimura
Atsutoshi Yoshimura

28 July 2023 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
FFFatima Farhana
Fatima Farhana
ESEiko Sakai
Eiko Sakai
YKYu Koyanagi
Yu Koyanagi
YYYu Yamaguchi
Yu Yamaguchi
Mohammad Ibtehaz AlamMohammad Ibtehaz Alam
Mohammad Ibtehaz Alam
Takayuki TsukubaTakayuki Tsukuba
Takayuki Tsukuba